-
Je něco špatně v tomto záznamu ?
Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer
C. Šálek, P. Mináriková, L. Benešová, V. Nosek, R. Strnad, M. Zavoral, M. Minárik
Jazyk angličtina Země Řecko
Typ dokumentu práce podpořená grantem
NLK
Free Medical Journals
od 2004 do Před 2 roky
Open Access Digital Library
od 2004-01-01
PubMed
19443408
Knihovny.cz E-zdroje
- MeSH
- alely MeSH
- analýza přežití MeSH
- chromozomální delece MeSH
- geny p53 MeSH
- geny ras MeSH
- lidé MeSH
- lidské chromozomy, pár 18 MeSH
- lidské chromozomy, pár 9 MeSH
- mutace MeSH
- nádory slinivky břišní genetika MeSH
- prognóza MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
BACKGROUND: K-ras mutations and allelic losses of tumor suppressors p16 and DPC4 are perceived as potential markers for screening of pancreatic malignancy. In this study, molecular data is compared with survival statistics of the patients and whether they correlate with patients' prognosis is questioned. PATIENTS AND METHODS: Fifty three consecutive patients with advanced pancreatic cancer (stage III and IV) who underwent EUS-guided fine needle aspiration (FNA) were enrolled into the study (28 males, 25 females, 63+/-10.5 years). Samples were evaluated on-site for presence of malignant cells. DNA was extracted from Giemsa stained smears using laser microdissection, and mutation status of K-ras and p53 was tested by cycling-gradient capillary electrophoresis (CGCE). In addition, allelic losses of tumor suppressor genes p16 (INK4, CDKN2A) and DPC4 (MADH4, SMAD4) were detected by monitoring the loss of heterozygosity (LOH) at 9p and 18q loci. Molecular data were compared with survival statistics using Kaplan-Meier method. RESULTS: The median survival in K-ras positive group was 7.0+/-2.4 months (95% CI 2.3-11.7) and in K-ras negative group was 10.0+/-0.6 months (95% CI 8.7-11.3). The median survival in p53 positive group was 10.0+/-2.2 months (95% CI 5.6-14.4) and in p53 negative group was 6.0+/-2.5 months (95% CI 1.1-10.9). The median survival in LOH 9p positive group was 9.0+/-5.1 months (95% CI 0-18.9), in LOH 9p negatives was 10.0+/-5.0 months (95% CI 0.2-19.8). The median survival in LOH 18q positive group was 10.0+/-4.2 months (95% CI 1.8-18.2) and in LOH 18q negative group was 3.0+/-1.3 months (95% CI 0.5-5.5). After the adjustment for age using Cox proportional hazards model, none of the evaluated molecular markers was shown to be an independent prognostic marker for survival of patients with pancreatic cancer. CONCLUSION: None of the studied molecular markers was identified as an independent factor determining survival prognosis.
- 000
- 03450naa 2200409 a 4500
- 001
- bmc11019682
- 003
- CZ-PrNML
- 005
- 20120327145944.0
- 008
- 110714s2009 gr e eng||
- 009
- AR
- 035 __
- $a (PubMed)19443408
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Šálek, Cyril, $d 1977- $7 xx0098743
- 245 10
- $a Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer / $c C. Šálek, P. Mináriková, L. Benešová, V. Nosek, R. Strnad, M. Zavoral, M. Minárik
- 314 __
- $a Laboratory for Molecular Genetics and Oncology, Genomac International Ltd., Bavorska 856, 15541 Prague 5, Czech Republic.
- 520 9_
- $a BACKGROUND: K-ras mutations and allelic losses of tumor suppressors p16 and DPC4 are perceived as potential markers for screening of pancreatic malignancy. In this study, molecular data is compared with survival statistics of the patients and whether they correlate with patients' prognosis is questioned. PATIENTS AND METHODS: Fifty three consecutive patients with advanced pancreatic cancer (stage III and IV) who underwent EUS-guided fine needle aspiration (FNA) were enrolled into the study (28 males, 25 females, 63+/-10.5 years). Samples were evaluated on-site for presence of malignant cells. DNA was extracted from Giemsa stained smears using laser microdissection, and mutation status of K-ras and p53 was tested by cycling-gradient capillary electrophoresis (CGCE). In addition, allelic losses of tumor suppressor genes p16 (INK4, CDKN2A) and DPC4 (MADH4, SMAD4) were detected by monitoring the loss of heterozygosity (LOH) at 9p and 18q loci. Molecular data were compared with survival statistics using Kaplan-Meier method. RESULTS: The median survival in K-ras positive group was 7.0+/-2.4 months (95% CI 2.3-11.7) and in K-ras negative group was 10.0+/-0.6 months (95% CI 8.7-11.3). The median survival in p53 positive group was 10.0+/-2.2 months (95% CI 5.6-14.4) and in p53 negative group was 6.0+/-2.5 months (95% CI 1.1-10.9). The median survival in LOH 9p positive group was 9.0+/-5.1 months (95% CI 0-18.9), in LOH 9p negatives was 10.0+/-5.0 months (95% CI 0.2-19.8). The median survival in LOH 18q positive group was 10.0+/-4.2 months (95% CI 1.8-18.2) and in LOH 18q negative group was 3.0+/-1.3 months (95% CI 0.5-5.5). After the adjustment for age using Cox proportional hazards model, none of the evaluated molecular markers was shown to be an independent prognostic marker for survival of patients with pancreatic cancer. CONCLUSION: None of the studied molecular markers was identified as an independent factor determining survival prognosis.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a alely $7 D000483
- 650 _2
- $a chromozomální delece $7 D002872
- 650 _2
- $a lidské chromozomy, pár 18 $7 D002887
- 650 _2
- $a lidské chromozomy, pár 9 $7 D002899
- 650 _2
- $a geny p53 $7 D016158
- 650 _2
- $a geny ras $7 D011905
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a nádory slinivky břišní $x genetika $7 D010190
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a analýza přežití $7 D016019
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Mináriková, Petra $7 xx0054190
- 700 1_
- $a Mináriková, Lucie, $d 1974- $7 xx0105258
- 700 1_
- $a Nosek, Vladimír $7 xx0095912
- 700 1_
- $a Strnad, Robin, $d 1968- $7 xx0061410
- 700 1_
- $a Zavoral, Miroslav, $d 1953- $7 xx0036686
- 700 1_
- $a Minárik, Marek, $d 1970- $7 xx0071043
- 773 0_
- $t Anticancer Research $g Roč. 29, č. 5 (2009), s. 1803-1810 $x 0250-7005 $w MED00000478
- 910 __
- $a ABA008 $b x $y 2
- 990 __
- $a 20110715115251 $b ABA008
- 991 __
- $a 20120327145927 $b ABA008
- 999 __
- $a ok $b bmc $g 864510 $s 729561
- BAS __
- $a 3
- BMC __
- $a 2009 $b 29 $c 5 $d 1803-1810 $i 0250-7005 $m Anticancer research $n Anticancer Res $x MED00000478
- LZP __
- $a 2011-3B09/Bjvme